Table 2.
Demographic and clinical characteristics of patients of therapeutic dose group of rivaroxaban compared to warfarin.
| Patients' characteristics | Therapeutic dose group of rivaroxaban | Warfarin |
p value |
|---|---|---|---|
| (N = 87) | (N = 153) | ||
| Mean age ± SD | 69.94 ± 15.24 | 71.35 ± 13.09 | 0.7088 |
|
| |||
| Age ≥ 65 | 59 (67.82%) | 104 (67.97%) | 0.98 |
| Age < 65 | 28 (32.18%) | 49 (32.03) | |
|
| |||
| Gender | |||
| Female | 39 (44.83%) | 83 (54.25%) | 0.1605 |
| Male | 48 (55.17%) | 70 (45.75%) | |
|
| |||
| Ethnic group | |||
| White | 66 (75.86%) | 133 (86.93%) | 0.285 |
| AA | 12 (13.79%) | 4 (2.61%) | |
| Others | 9 (10.35%) | 16 (10.46%) | |
|
| |||
| Indication for drug |
|||
| AF | 67 (77.01%) | 93 (60.78%) | <0.0001† |
| VTE treatment | 12 (13.79%) | 56 (36.60%) | |
| VTE prophylaxis | 2 (2.30%) | 2 (1.31%) | |
| Other | 6 (6.90%) | 2 (1.31%) | |
|
| |||
| Mean duration being on drug (Days) ± SD | 125.30 ± 131.00 | 252.95 ± 167.91 | <0.0001† |
|
| |||
| Duration ≤40 days | 31 (35.63%) | 16 (10.46%) | <0.0001† |
|
| |||
| Concomitant with aspirin | 44 (50.58%) | 63 (41.18%) | 0.0008† |
|
| |||
| Concomitant with thienopyridine | 11 (12.64%) | 27 (17.65%) | 0.3074 |
|
| |||
| Dual antiplatelet agents | 8 (9.20%) | 15 (9.80%) | 0.8776 |
|
| |||
| Concomitant with NSAIDs | 8 (9.20%) | 7 (4.58%) | 0.2187 |
|
| |||
| Hb < 12 | 27 (32.14%) | 54 (35.29%) | 0.0803 |
| Missing data | 3 | 0 | |
|
| |||
| Cr > 1.5 | 5 (5.95%) | 15 (9.80%) | 0.1134 |
| Missing data | 3 | 0 | |
|
| |||
| GFR ≤ 30 | 1 (1.20%) | 6 (3.92%) | 0.5645 |
| Missing data | 3 | 0 | |
|
| |||
| ALT > 40 | 8 (10.26%) | 28 (20%) | 0.1081 |
| Missing data | 9 | 13 | |
|
| |||
| BMI | |||
| <18.5 | 3 (3.45%) | 0 (0%) | 0.4152 |
| 18.5–24.9 | 21 (24.14%) | 35 (22.88%) | |
| >25 | 63 (72.41%) | 118 (77.12%) | |
| Missing data | 0 | 0 | |
|
| |||
| Previous GI bleeding | 4 (4.60%) | 15 (9.80%) | 0.1551 |
AA: African American, AF: atrial fibrillation, ALT: alanine aminotransferase, BMI: body mass index, Cr: creatinine, GFR: glomerular filtration rate, GI: gastrointestinal, Hb: hemoglobin, NSIADs: nonsteroidal anti-inflammatory drugs, and VTE: venous thromboembolism events. †Signifying statistical significant values.